Story perspectives

AstraZeneca Celebrates Oncology Advances Amid Ongoing Challenges

12/23/2025

Summary

Story summary

AstraZeneca celebrated its 2025 Oncology achievements at San Antonio Breast Cancer Symposium, highlighting the US Breast Cancer team's progress in metastatic breast cancer.
Clinicians face ongoing challenges in clinical utility and biomarker identification.
UConn Health partnered with Connecticut Department of Public Health to expand cancer prevention and treatment, backed by $525,000 in federal funding.
The American Society of Hematology (ASH) Meeting highlighted multiple myeloma therapies and shift to earlier treatment.

1 of 1

Story summary

AstraZeneca celebrated its 2025 Oncology achievements at San Antonio Breast Cancer Symposium, highlighting the US Breast Cancer team's progress in metastatic breast cancer.
Clinicians face ongoing challenges in clinical utility and biomarker identification.
UConn Health partnered with Connecticut Department of Public Health to expand cancer prevention and treatment, backed by $525,000 in federal funding.
The American Society of Hematology (ASH) Meeting highlighted multiple myeloma therapies and shift to earlier treatment.